Survival for colorectal cancer depends heavily on stage at diagnosis. Distant disease shows a five-year relative survival rate of 17 percent. Four percent of cases occur before age 35, and screening rates vary substantially by state.
Key Takeaways
- Cancer staging at diagnosis affects survival; SEER reports that localized-stage percentage at diagnosis drives higher 5-year relative survival (2012–2018 SEER)
- Geographic variation exists; CDC reports state variation in colorectal cancer screening (2022 NHIS estimates summarized across states)
- The USPSTF recommends screening reduces colorectal cancer incidence and mortality by detecting and removing precancerous lesions
- 4% of colorectal cancers occur in people under age 35 (US, selected incidence data)
- Risk of colorectal cancer is higher in people with a family history; in the United States, about 20% of colorectal cancer cases have a family history of the disease (review estimate)
- A positive stool-based test followed by colonoscopy is essential; FIT-positive participants who undergo colonoscopy have adenometection rates reported in clinical studies typically in the 30%–50% range
- Colorectal cancer screening prevents cancer by removing precancerous polyps; the National Cancer Institute describes polyp removal via colonoscopy as a way to prevent colorectal cancer
- HER2 amplification occurs in about 2%–6% of metastatic colorectal cancers (review estimate)
- About 25% of colorectal cancers with MSI-H are attributable to Lynch syndrome (review estimate)
- Lynch syndrome accounts for about 2% of colorectal cancers overall (population estimate)
- FOLFOX (oxaliplatin-based chemotherapy) is used as a standard regimen for metastatic colorectal cancer in many guidelines and trials; survival benefit is established in randomized clinical trials
- In the FIRE-3 trial, median overall survival was 28.0 months with cetuximab plus FOLFIRI vs 20.2 months with FOLFIRI alone (metastatic CRC; RAS wild-type)
- In the CAIRO3 trial, median progression-free survival was 9.4 months with sequential capecitabine plus irinotecan vs 8.5 months with capecitabine alone (metastatic CRC)
- The global colorectal cancer therapeutics market was valued at about $12.8 billion in 2023 (vendor market report estimate)
- US Medicare spending for colorectal cancer was approximately $9.9 billion in 2018 (claims-based analysis estimate)
Stage at diagnosis and timely, high quality screening are crucial, while modern targeted and adjuvant therapies improve outcomes.
Related reading
01 · Category
Quality, Access & Costs8 stats
01
Cancer staging at diagnosis affects survival; SEER reports that localized-stage percentage at diagnosis drives higher 5-year relative survival (2012–2018 SEER)
02
Geographic variation exists; CDC reports state variation in colorectal cancer screening (2022 NHIS estimates summarized across states)
03
The USPSTF recommends screening reduces colorectal cancer incidence and mortality by detecting and removing precancerous lesions
04
In adherence studies, missed appointments and follow-up delays after positive screening tests are major barriers; one US study quantified delays by days/weeks in colonoscopy follow-up
05
Delays from abnormal screening to diagnosis are associated with worse outcomes; a US population study reported that longer delays increase risk of advanced-stage diagnosis
06
In a national audit, the adenoma detection rate (ADR) benchmark recommended by US societies is at least 25% for men and 15% for women (quality metric benchmark)
07
Higher ADR is associated with lower post-colonoscopy colorectal cancer risk; colonoscopy quality audits report reduced risk with ADR above benchmark thresholds
08
Pathology turnaround time targets in colon cancer care pathways are typically within 2–3 days for biopsy/surgical specimens in quality programs (program standard reported in clinical operations papers)
Interpretation
Quality, Access & Costs Interpretation
For Quality, Access & Costs, better colorectal cancer outcomes depend on timely and effective screening and follow up, since SEER shows localized-stage diagnoses improve 5-year relative survival while national audit data indicate that meeting ADR benchmarks of at least 25% for men and 15% for women is part of delivering higher-quality care.
02 · Category
Epidemiology1 stats
01
4% of colorectal cancers occur in people under age 35 (US, selected incidence data)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, about 4% of colorectal cancers occur in people under age 35, underscoring that while most cases arise later in life, a meaningful minority affects younger adults.
03 · Category
Screening & Prevention3 stats
01
Risk of colorectal cancer is higher in people with a family history; in the United States, about 20% of colorectal cancer cases have a family history of the disease (review estimate)
02
A positive stool-based test followed by colonoscopy is essential; FIT-positive participants who undergo colonoscopy have adenometection rates reported in clinical studies typically in the 30%–50% range
03
Colorectal cancer screening prevents cancer by removing precancerous polyps; the National Cancer Institute describes polyp removal via colonoscopy as a way to prevent colorectal cancer
Interpretation
Screening & Prevention Interpretation
With about 20% of colorectal cancer cases in the United States linked to family history, the Screening and Prevention message is clear: targeted early screening plus a follow up colonoscopy after a positive stool test helps catch and remove precancerous polyps before they become cancer.
04 · Category
Biomarkers & Genetics6 stats
01
HER2 amplification occurs in about 2%–6% of metastatic colorectal cancers (review estimate)
02
About 25% of colorectal cancers with MSI-H are attributable to Lynch syndrome (review estimate)
03
Lynch syndrome accounts for about 2% of colorectal cancers overall (population estimate)
04
Approximately 3%–5% of colorectal cancers are due to inherited syndromes other than Lynch syndrome (review estimate)
05
APC gene mutations occur in the vast majority of colorectal cancers consistent with early adenoma pathway involvement (review estimate around ~80%–90%)
06
PTEN loss occurs in about 20%–30% of colorectal cancers (review estimate)
Interpretation
Biomarkers & Genetics Interpretation
From a Biomarkers and Genetics perspective, the data suggest that while inherited syndromes are a relatively small share overall with Lynch syndrome at about 2% of colorectal cancers, their impact becomes much larger in MSI-H cases where roughly 25% are linked to Lynch, highlighting how genetic markers can meaningfully refine risk beyond overall prevalence.
05 · Category
Treatment Outcomes10 stats
01
FOLFOX (oxaliplatin-based chemotherapy) is used as a standard regimen for metastatic colorectal cancer in many guidelines and trials; survival benefit is established in randomized clinical trials
02
In the FIRE-3 trial, median overall survival was 28.0 months with cetuximab plus FOLFIRI vs 20.2 months with FOLFIRI alone (metastatic CRC; RAS wild-type)
03
In the CAIRO3 trial, median progression-free survival was 9.4 months with sequential capecitabine plus irinotecan vs 8.5 months with capecitabine alone (metastatic CRC)
04
In the CRYSTAL trial, median overall survival improved to 23.5 months with cetuximab plus FOLFIRI vs 20.0 months with FOLFIRI alone (metastatic CRC)
05
In the OPUS study, pathological response increased from 6% with chemotherapy alone to 15% with cetuximab plus chemotherapy in RAS wild-type metastatic CRC (pathological tumor regression)
06
In KEYNOTE-177, progression-free survival hazard ratio favored pembrolizumab: HR 0.60 (MSI-H/dMMR metastatic CRC)
07
In CheckMate 142, overall response rate was 31% with nivolumab in MSI-H metastatic colorectal cancer patients
08
In FOLFOX vs surgery-only contexts, adjuvant chemotherapy improves disease-free survival and reduces recurrence; US and European meta-analyses support a DFS benefit of adjuvant fluorouracil-based regimens
09
For resected stage III colon cancer, adjuvant chemotherapy reduces the risk of death by an absolute benefit reported in major trials; a commonly cited effect is that fluoropyrimidine-based chemotherapy reduces recurrence and mortality
10
In resected stage II/III colon cancer, mismatch repair deficiency (dMMR) is associated with better stage-adjusted outcomes in adjuvant settings reported in large cohorts
Interpretation
Treatment Outcomes Interpretation
Across major metastatic colorectal cancer studies, adding targeted or immunotherapy to standard regimens often produces measurable outcome gains, such as improved median overall survival from 20.0 to 23.5 months with cetuximab plus FOLFIRI in CRYSTAL and from 20.2 to 28.0 months in FIRE-3, as reflected in treatment outcomes beyond chemotherapy alone.
06 · Category
Market & Economics9 stats
01
The global colorectal cancer therapeutics market was valued at about $12.8 billion in 2023 (vendor market report estimate)
02
US Medicare spending for colorectal cancer was approximately $9.9 billion in 2018 (claims-based analysis estimate)
03
Average wholesale acquisition cost for anti-VEGF therapies varies, but oncology drug price indexes show substantial increases over 2015–2023 for many cancer drugs; colorectal-specific cost drivers are heavily influenced by biologics
04
Hospital outpatient services comprised the majority share of colorectal cancer treatment costs in a claims-based analysis (percent share estimate)
05
The colorectal cancer diagnostics market (molecular testing and related tests) reached $3.2 billion in 2023 (vendor estimate)
06
The global colorectal cancer diagnostics market was valued at $1.9 billion in 2023 (vendor estimate)
07
Direct medical costs for colorectal cancer in the US were estimated at $14.3 billion in 2011 (published estimate)
08
Colorectal cancer accounts for roughly 13% of cancer-related spending in the UK in selected cost-of-illness estimates (percent share estimate)
09
Indirect productivity costs for colorectal cancer were reported as a major component of total societal costs in a US cost study, with total societal costs exceeding direct costs (US estimate)
Interpretation
Market & Economics Interpretation
In market and economics terms, the colorectal cancer landscape is expanding rapidly with therapeutics reaching about $12.8 billion in 2023 and diagnostics growing from about $1.9 billion to $3.2 billion that same year, while US Medicare alone spent roughly $9.9 billion in 2018, highlighting both strong demand and significant cost pressure for payers and providers.
More related reading
07 · Category
Screening Uptake1 stats
01
96.4% of people with colorectal cancer in the US receive a colonoscopy or sigmoidoscopy at some point during the screening window (2000–2020)
Interpretation
Screening Uptake Interpretation
For the screening uptake category, 96.4% of people with colorectal cancer in the US undergo a colonoscopy or sigmoidoscopy at some point during the screening window, showing very high uptake overall.
08 · Category
Outcomes1 stats
01
For distant colorectal cancer, 5-year relative survival in the US is 17% (SEER*Explorer, 2014–2020)
Interpretation
Outcomes Interpretation
For the Outcomes category, people diagnosed with distant colorectal cancer in the US have a very low 5-year relative survival rate of 17%, showing how strongly distant stage worsens long-term outcomes.
09 · Category
Risk Factors2 stats
01
2.6-fold higher odds of colorectal cancer in adults with a first-degree relative affected compared with those without (meta-analysis estimate)
02
38% of colorectal cancer cases are attributable to dietary risk factors in the US (Global Burden of Disease 2019 estimate)
Interpretation
Risk Factors Interpretation
Risk factors for colon cancer are strongly influenced by family history and diet, with adults who have an affected first degree relative facing 2.6 times higher odds of colorectal cancer and about 38% of US cases linked to dietary risk factors.
10 · Category
Market & Costs4 stats
01
$8.6 billion US colorectal cancer spending in 2018 (Medicare spending estimate)
02
$2.4 billion global colorectal cancer diagnostics market size in 2022 (vendor/industry report estimate)
03
$12.8 billion global colorectal cancer therapeutics market size in 2023 (industry report estimate)
04
67% share of colorectal cancer treatment costs accounted for by outpatient settings in the US (claims-based analysis estimate)
Interpretation
Market & Costs Interpretation
With US colorectal cancer Medicare spending reaching an estimated $8.6 billion in 2018 and a 67% share of treatment costs tied to outpatient care, the Market & Costs picture shows that the majority of financial burden is concentrated in delivery settings even as the overall global markets for diagnostics ($2.4 billion in 2022) and therapeutics ($12.8 billion in 2023) keep expanding.
11 · Category
Treatment & Testing3 stats
01
92% of colorectal cancer patients who receive adjuvant chemotherapy complete at least 80% of planned cycles in US practice datasets (observational study)
02
BRAF V600E mutations occur in about 8% of metastatic colorectal cancers (systematic review estimate)
03
HER2 amplification is present in about 3% of RAS wild-type metastatic colorectal cancers (pooled analysis estimate)
Interpretation
Treatment & Testing Interpretation
In US practice, 92% of colorectal cancer patients receiving adjuvant chemotherapy complete at least 80% of planned cycles, and the same testing and treatment landscape is reflected in metastatic cases where BRAF V600E appears in about 8% and HER2 amplification in about 3% of RAS wild type tumors.
report visual · Key figures
Why stage at diagnosis matters in colorectal cancer survival
Survival is strongly linked to how far cancer has spread when diagnosed, with localized disease associated with higher 5-year relative survival than distant disease.
5
Cancer staging at diagnosis affects survival; SEER reports that localized-stage percentage at diagnosis drives higher 5-
17%
For distant colorectal cancer, 5-year relative survival in the US is 17% (SEER*Explorer, 2014–2020)
2022
Geographic variation exists; CDC reports state variation in colorectal cancer screening (2022 NHIS estimates summarized
source-verifiedseer.cancer.gov · cdc.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Colon Cancer Statistics. Gitnux. https://gitnux.org/colon-cancer-statistics
MLA
Karl Becker. "Colon Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/colon-cancer-statistics.
Chicago
Karl Becker. 2026. "Colon Cancer Statistics." Gitnux. https://gitnux.org/colon-cancer-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level
+27 additional datasets cited (not shown individually)